2024-513005-31-00招募中3 期
AMBRE : Open-label, randomized, multicenter, phase III study, comparing standard chemotherapy to standard combination of endocrine therapy with Abemaciclib as initial Metastatic treatment among patients with visceral metastasis of ER+ HER2- BREast cancer, high burden disease.
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Unicancer
- 入组人数
- 180
- 试验地点
- 41
- 主要终点
- Progression-free survival (PFS) will be measured from the date of randomization until the date of event defined as the first documented progression (RECIST v1.1) or death from any cause. Patients with no event at the time of the analysis will be censored at the date of the last available tumor assessment or last follow-up visit whichever comes first. The patients free of progression who switched to another therapy will be censored at the time of the treatment change (RECIST v1.1)
研究概览
简要总结
The primary objective is to compare the efficacy of standard Endocrine Therapy + Abemaciclib combination versus standard Chemotherapy based on progression-free survival (PFS), in patients with visceral metastases of ER+ HER2- breast cancer, high tumor burden.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Patient must have signed a written informed consent form prior to any study specific procedures
- •ER-positive by IHC (>10%) on primary or metastatic disease
- •HER2-negative by IHC (score 0 or 1+) and/or Fish/Cish negative
- •Non-menopausal women will receive LH-RH agonists before starting the endocrine therapy and every 28 days thereafter. It is recommended that LHRH agonist therapy be started approximately 28 days before the start of hormone therapy
- •Adequate renal, hepatic, and hematopoietic functions as defined by the following criteria: Absolute Neutrophil Count (ANC) ≥ 1,500/mm3 or ≥ 1.5 G/L
- •Adequate renal, hepatic, and hematopoietic functions as defined by the following criteria: Platelets ≥ 100,000/mm3 or ≥ 100 G/L
- •Adequate renal, hepatic, and hematopoietic functions as defined by the following criteria: Hemoglobin ≥ 8 g/dL (patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion)
- •Adequate renal, hepatic, and hematopoietic functions as defined by the following criteria: Serum Aspartate Transaminase (AST) and serum Alanine Aminotransferase Transaminase (ALT) ≤ 3 x upper limit of normal (ULN) (< 5 ULN if liver metastasis)
- •Adequate renal, hepatic, and hematopoietic functions as defined by the following criteria: Total serum bilirubin ≤ 1.5 x ULN (patients with Gilbert’s syndrome with a total bilirubin ≤ 2.0 times ULN and direct bilirubin within normal limits are permitted)
- •Adequate renal, hepatic, and hematopoietic functions as defined by the following criteria: Serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance > 60 mL/min as calculated using the standard method for the institution
- •Women of childbearing potential agreeing to use highly effective contraception during treatment and for 3 weeks following the last dose of abemaciclib or for 6 months following the last dose of capecitabine or paclitaxel or for 2 years following the last dose of fulvestrant
- •Female age ≥ 18 years
- •Women of childbearing potential must have a negative serum pregnancy test within 7 days and/or urine pregnancy test 48 hours prior to the administration of any study treatment
- •Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures
- •Health insurance coverage
- •Performance status, ECOG 0-2
- •Histologically confirmed adenocarcinoma of the breast
- •Metastatic breast cancer, with liver and/or lung and/or pleural and/or peritoneal metastases with high tumor burden (according to RECIST v1.1) defined as either visceral involvement of one site with more than 3 lesions
- •Metastatic breast cancer, with liver and/or lung and/or pleural and/or peritoneal metastases with high tumor burden (according to RECIST v1.1) defined as either visceral involvement of at least 2 sites
- •Metastatic breast cancer, with liver and/or lung and/or pleural and/or peritoneal metastases with high tumor burden (according to RECIST v1.1) defined as either symptomatic ascites or pleural effusion, defined as the need for weekly drainage with visceral measurable metastases
- •Metastatic breast cancer, with liver and/or lung and/or pleural and/or peritoneal metastases with high tumor burden (according to RECIST v1.1) defined as either visceral involvement and LDH > N
- •Patient considered candidate for a first line chemotherapy in metastatic setting by their physician (either capecitabine or paclitaxel) and who may receive first-line endocrine therapy combined with abemaciclib according to the marketed authorization
排除标准
- •Bone lesion only or non-measurable lesion (RECIST V1.1)
- •Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix or the breast, and adequately treated basal cell or squamous cell carcinoma of the skin
- •Patient has active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment
- •Patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
- •Patient has any serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance < 30 mL/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn’s disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea)
- •Any drug or plant derivative that may interact with abemaciclib
- •Episode of pulmonary thromboembolism (PTE) in the last six months. Patients with deep vein thrombosis previously treated with a low-molecular-weight heparin for more than two months prior enrolment in the study will be eligible
- •Patients with previously documented total/partial dihydropyrimidine dehydrogenase (DPD) deficiency or with DPD deficiency identified at baseline visit (plasma uracil concentration ≥ 16 ng/mL). These patients will be not eligible for chemotherapy by capecitabine
- •Pregnant or breast feeding women.
- •Patients enrolled in another therapeutic study within 30 days prior inclusion
- •Individuals deprived of liberty or placed under the authority of a tutor
- •Patients with all target lesions in a previously irradiated region, except if clear progression has been observed prior to study in at least one of them
- •Spinal cord compression and/or symptomatic or progressive brain metastases (Brain metastasis are not acceptable unless asymptomatic or treated and stable off steroids for at least 30 days prior to start of study drug)
- •Patient with visceral crisis as defined in the 4th ESO–ESMO International Consensus Guidelines (severe organ dysfunction as assessed by signs and symptoms, laboratory studies and rapid progression of disease)
- •Patient has received one line of chemotherapy for metastatic disease
- •Patient has received endocrine therapy for metastatic disease
- •Inability to swallow orally administered medication
- •Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization
- •Major problem with intestinal absorption
结局指标
主要结局
Progression-free survival (PFS) will be measured from the date of randomization until the date of event defined as the first documented progression (RECIST v1.1) or death from any cause. Patients with no event at the time of the analysis will be censored at the date of the last available tumor assessment or last follow-up visit whichever comes first. The patients free of progression who switched to another therapy will be censored at the time of the treatment change (RECIST v1.1)
Progression-free survival (PFS) will be measured from the date of randomization until the date of event defined as the first documented progression (RECIST v1.1) or death from any cause. Patients with no event at the time of the analysis will be censored at the date of the last available tumor assessment or last follow-up visit whichever comes first. The patients free of progression who switched to another therapy will be censored at the time of the treatment change (RECIST v1.1)
次要结局
- In both arms throughout treatments A focus will be done at 24 weeks: the progression-free survival (PFS) within 24 weeks will be estimated from the date of randomization until the date of event defined as the first documented progression (RECIST v1.1) or death from any cause
- In both arms throughout treatments EORTC QLQ-C30 and QLQ-BR23 questionnaires will be used in the measurement of patients’ quality of life. All dimensions will be available at baseline and every 6 weeks during 24 weeks. G8 questionnaire will also be requested at baseline for patient older than 70
- In both arms throughout treatments Radiological response rates in each treatment arm will be determined according to RECIST v1.1: The overall response rate (ORR) will be defined as the proportion of randomized patients who achieve a complete response (CR) or a partial response (PR) at 24 weeks
- In both arms throughout treatments Radiological response rates in each treatment arm will be determined according to RECIST v1.1: The duration of response (DoR) will be defined as the duration between the time of tumor response (CR or PR) until the date of objective progression
- In both arms throughout treatments PFS1: Defined as the interval between the date of randomization and the date of progression or death from any cause regardless of whether the patient withdraws from randomized study treatment or receives another anti-cancer therapy prior to progression
- In both arms throughout treatments PFS2 : Time from randomization to second progression is defined as the time from the date of randomization to the earliest of the progression event subsequent to that used for the primary variable PFS, or date of death (i.e., objective radiological, CA15-3 or symptomatic progression)
- In both arms throughout treatments PFS1 and PFS2 in subgroups defined by stratification factors
- In both arms throughout treatments Overall survival (OS) is defined as the interval between the date of randomization and the date of death from any cause
- In both arms throughout treatments Safety will be evaluated according to the CTCAE V5.0
- In patients randomized in Chemotherapy arm: Type of maintenance regimens administered after the end of the standard treatment by chemotherapy and in the absence of disease progression
- Serial CTC counts will be performed using the CellSearch® system on blood samples to assess predictive and prognostic value of CTC status on overall response rate, PFS within 24 weeks, PFS1 and PFS2 respectively
研究者
Nourredine AIT RAHMOUNE
Scientific
Unicancer
研究点 (41)
Loading locations...
相似试验
招募中
3 期
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) intermediate to high risk, HR+/HER2- early breast cancer (ADAPTlate)2023-509242-35-00WSG Westdeutsche Studiengruppe GmbH1,700
尚未招募
2 期
Adebrelimab Combined With Induction Chemotherapy or SHR-8068 for Mismatch Repair-Deficient/Microsatellite Instability-High (dMMR/MSI-H) Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma：A Randomized, Non-comparative Phase 2 StudyNCT07266025Shanghai Zhongshan Hospital30
招募中
2 期
Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 TrialGlioblastomaNCT07263438Centre Hospitalier Universitaire Vaudois59
尚未招募
3 期
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye DiseaseNCT07262476Minghui Pharmaceutical (Hangzhou) Ltd258
进行中（未招募）
1/2 期
A clinical trial to evaluate the safety and effectiveness of a combination of either AG-12or AG-221 tablets with azacitidine injections in patients withnewly diagnosed Acute Myeloid Leukemia (AML) and who have mutations in enzymes isocitrate dehydrogenase 1 or 2 (IDH 1 or IDH2) and are not candidates to receive intensive induction chemotherapy.2024-511722-31-00Celgene Corp.70